Journal
DIABETES-METABOLISM RESEARCH AND REVIEWS
Volume 25, Issue 4, Pages 302-306Publisher
WILEY
DOI: 10.1002/dmrr.933
Keywords
type 1 diabetes; anti-CD3 antibody; immune modulation; immunologic tolerence
Categories
Funding
- JDRF [2006-351, 2007502, 2007-1059, UL1 M02139]
- Brehm Foundation
- Friends United for Diabetes Research
- [RO1 DK DK057846]
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057846] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The use of anti-CD3 monoclonal antibodies (mAbs) has moved from the bench to the bedside. The experience with the anti-human CD3 mAb OKT3 for treatment of transplant rejection identified limitations that were largely overcome with the creation of humanized non-FcR binding antibodies: Teplizumab, Otelixizumab and Visilizumab. Preclinical studies showed the ability of the drugs to reverse hyperglycaemia in diabetic non-obese diabetic (NOD) mice providing rationale for clinical trials with the agents. The former two drugs have been tested in subjects with new onset type 1 diabetes. They have both shown, in randomized clinical trials, an ability to reduce the loss of insulin production over the first 2 years of the disease. In addition, the need for exogenous insulin to maintain glucose control has been reduced. However, these agents alone do not restore normal glucose control, and future approaches will likely require combinations of agents with complementary immune or metabolic activity. Copyright (C) 2009 John Wiley & Sons, Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available